文献速递甲状腺疾病

迈向个体化促甲状腺激素参考范围:三个独立队列的遗传与人群方法研究

Towards Personalized TSH Reference Ranges: A Genetic and Population-Based Approach in Three Independent Cohorts.
PubMed 文献 · Thyroid · 2024-07-15

研究用包含59个遗传变异的促甲状腺激素(TSH)多基因评分(PGS)在无甲状腺疾病的队列(n=6,834)中计算遗传决定的TSH参考范围,并与人群参考范围比较诊断重分类情况,随后在两个独立人群队列中验证(n=3,800;n=26,321,另含左甲状腺素治疗者n=1,132)。PGS对个体TSH浓度的预测力远强于游离甲状腺素(FT4)等非遗传因素,应用遗传决定的参考范围可使原被判为亚临床甲减或甲亢者中最高24.7-30.1%重分类为甲状腺功能正常。

要点

  • PGS对TSH浓度总变异的解释度为9.2-11.1%,高于FT4的2.4-2.7%及任何非遗传因素的0.2-1.8%。
  • 应用遗传决定的TSH参考范围后,原按人群参考范围判为亚临床甲减或甲亢者中最高24.7-30.1%重分类为甲状腺功能正常。
  • PGS较高四分位者接受左甲状腺素(LT4)处方的概率高于较低四分位者(Q1为3.3% vs Q4为5.2%,趋势P=1.7×10-8)。

核心结论

  • 个体遗传特征有潜力实现TSH参考范围个体化,对诊断重分类和LT4处方有较大影响。
  • 由于目前所用PGS仅能预测约10%的TSH个体间变异,未来发现更多决定TSH浓度的遗传变异时应进一步完善该评分。

研究设计与样本

  • 采用包含59个遗传变异的PGS,在无甲状腺疾病队列(n=6,834)中计算遗传决定的TSH参考范围,并与人群参考范围比较诊断重分类。
  • 结果在第二个独立人群无甲状腺疾病队列(n=3,800)中验证。
  • 在第三个独立人群队列中评估潜在临床意义,该队列包括无甲状腺疾病个体(n=26,321)及接受左甲状腺素(LT4)治疗者(n=1,132)。

主要发现

  • PGS对TSH浓度的预测力远强于FT4(对TSH浓度总变异的解释度9.2-11.1% vs 2.4-2.7%)及任何其他非遗传因素(0.2-1.8%)。
  • 遗传决定的TSH参考范围在所有队列中均随PGS四分位显著不同,而FT4浓度的差异缺失或仅轻微。
  • 原按人群TSH参考范围判为亚临床甲减或甲亢者中,最多24.7-30.1%在应用遗传决定参考范围后重分类为甲状腺功能正常。
  • PGS较高四分位者接受LT4处方的概率高于较低四分位者(Q1为3.3% vs Q4为5.2%,趋势P=1.7×10-8)。

关键数值与推荐

  • PGS包含59个遗传变异。
  • PGS对TSH浓度总变异的解释度为9.2-11.1%,FT4为2.4-2.7%,非遗传因素为0.2-1.8%。
  • 重分类为甲状腺功能正常的比例为24.7-30.1%。
  • LT4处方比例Q1为3.3% vs Q4为5.2%,趋势P=1.7×10-8。

临床怎么用

  • 作者认为个体遗传特征有潜力实现TSH参考范围个体化,对诊断重分类和LT4处方有较大影响。
  • 作者认为目前PGS仅能预测约10%的TSH个体间变异,未来发现更多遗传变异时应进一步完善。

局限性

  • 目前所用PGS只能预测约10%的TSH个体间变异,需在发现更多决定TSH浓度的遗传变异后进一步完善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Serum thyroid-stimulating hormone (TSH) measurement is the diagnostic cornerstone for primary thyroid dysfunction. There is high inter-individual but limited intra-individual variation in TSH concentrations, largely due to genetic factors. The currently used wide population-based reference intervals may lead to inappropriate management decisions. Methods: A polygenic score (PGS) including 59 genetic variants was used to calculate genetically determined TSH reference ranges in a thyroid disease-free cohort (n = 6,834). Its effect on reclassification of diagnoses was investigated when compared to using population-based reference ranges. Next, results were validated in a second independent population-based thyroid disease-free cohort (n = 3,800). Potential clinical implications were assessed in a third independent population-based cohort including individuals without thyroid disease (n = 26,321) as well as individuals on levothyroxine (LT4) treatment (n = 1,132). Results: PGS was a much stronger predictor of individual TSH concentrations than FT4 (total variance in TSH concentrations explained 9.2-11.1% vs. 2.4-2.7%, respectively) or any other nongenetic factor (total variance in TSH concentrations explained 0.2-1.8%). Genetically determined TSH reference ranges differed significantly between PGS quartiles in all cohorts, while the differences in FT4 concentrations were absent or only minor. Up to 24.7-30.1% of individuals, previously classified as having subclinical hypo- and hyperthyroidism when using population-based TSH reference ranges, were reclassified as euthyroid when genetically determined TSH reference ranges were applied. Individuals in the higher PGS quartiles had a higher probability of being prescribed LT4 treatment compared to individuals from the lower PGS quartiles (3.3% in Q1 vs. 5.2% in Q4, Pfor trend =1.7 × 10-8). Conclusions: Individual genetic profiles have the potential to personalize TSH reference ranges, with large effects on reclassification of diagnosis and LT4 prescriptions. As the currently used PGS can only predict approximately 10% of inter-individual variation in TSH concentrations, it should be further improved when more genetic variants determining TSH concentrations are identified in future studies.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Kuś A, Sterenborg RBTM, Haug EB, et al. Towards Personalized TSH Reference Ranges: A Genetic and Population-Based Approach in Three Independent Cohorts. Thyroid. 2024. PMID: 38919119. doi:10.1089/thy.2024.0045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。